Storyline
Moderna Merck melanoma cancer vaccine 2026
One page that accretes the verified record as the story develops. Every fact keeps its date and its sources.
1 DAYS
5 FACTS
1 EVENTS
1 SOURCES
FIRST ENTRY OCT 22
OCT 22 · Day 1
Moderna and Merck cancer vaccine meets key endpoints in melanoma trial
A personalized mRNA cancer vaccine reduced the risk of disease recurrence in melanoma patients by 42% compared to standard treatment.
The vaccine is an individualized therapy that attacks unique mutations called neoantigens found in a patient's tumor.
The cancer vaccine was developed by Moderna and Merck.